（文章来源：证券日报） 证券日报网讯 1月7日，海辰药业在互动平台回答投资者提问时表示，公司硫化锂中试线产品各项参数 指标已达到要求，即将安排送样。四川洛辰是公司控股子公司安庆汇辰与赛科动力的合资公司，双方一 直在固态电池粘结剂的小试开发上紧密合作，该项目目前还处于小试开发阶段。 ...

格隆汇1月7日丨海辰药业(300584.SZ)在投资者互动平台表示，公司硫化锂中试线产品各项参数指标已 达到要求，即将安排送样。四川洛辰是公司控股子公司安庆汇辰与赛科动力的合资公司，双方一直在固 态电池粘结剂的小试开发上紧密合作，该项目目前还处于小试开发阶段。 ...

海辰药业（300584.SZ）1月7日在投资者互动平台表示，公司硫化锂中试线产品各项参数指标已达到要 求，即将安排送样。四川洛辰是公司控股子公司安庆汇辰与赛科动力的合资公司，双方一直在固态电池 粘结剂的小试开发上紧密合作，该项目目前还处于小试开发阶段。 每经AI快讯，有投资者在投资者互动平台提问：近期硫化物固态电池产业化加速，公司两个领域的进 展备受市场关注，1. 硫化锂方面，请问目前中试产能利用率（如日产量）、产品纯度？是否已送样至电 池企业（如赛科自身或其他合作电池厂）验证？2026年百吨级产能爬坡节奏？2. 固固接触粘接剂方面， 洛辰的小试工艺是否完成？粘接强度、界面阻抗是否符合行业领先水平？赛科动力在电池系统集成方面 的经验，是否为粘接剂量产提供支持？是否已送样电池厂性能验证？ （文章来源：每日经济新闻） ...

证券代码：300584 证券简称：海辰药业 公告编号：2026-001 南京海辰药业股份有限公司 关于控股股东、实际控制人股份全部解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、股东股份累计被质押的情况 截至公告披露日，曹于平先生及其妻子姜晓群女士所持质押股份情况如下： | | | | 本次解除 | 本次解除 | | | 已质押股份 情况 | | 未质押股份 情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | | 持股 | 质押前质 | 质押后质 | 占其所持 | 占公司总 | | | | | | 名称 | 持股数量 | 比例 | 押股份数 | 押股份数 | 股份比例 | 股本比例 | 已质押股份 限售和冻结 | 占已质押 | 未质押股份 限售和冻结 | 占未质押 | | | | | 量 | 量 | | | 数量 | 股份比例 | 数量 | 股份比例 | | 曹于平 | 50,491,306 | 42.08% | 4,000,00 ...

Group 1 - The company has initiated trial production for its VC project, indicating progress in its development phase [1] - The company acknowledges that it still needs to undergo a capacity ramp-up process, which is a critical step before full-scale production can be achieved [1]

Core Insights - The chemical pharmaceutical sector experienced a rise of 1.22% on December 17, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3870.28, up 1.19%, while the Shenzhen Component Index closed at 13224.51, up 2.4% [1] Group 1: Stock Performance - Hai Chen Pharmaceutical (300584) closed at 50.55, with a gain of 6.04% and a trading volume of 68,600 shares, amounting to a transaction value of 342 million yuan [1] - Other notable performers included Yahui Pharmaceutical (688176) with a closing price of 10.35, up 5.50%, and ST Renfu (600079) at 18.10, up 4.99% [1] - The overall trading volume and transaction values for various stocks in the sector indicate strong market activity, with ST Renfu recording a trading volume of 1.25 million shares and a transaction value of 2.173 billion yuan [1] Group 2: Fund Flow Analysis - The chemical pharmaceutical sector saw a net outflow of 554 million yuan from institutional investors, while retail investors contributed a net inflow of 799 million yuan [2][3] - The main stocks experiencing significant fund flow included ST Renfu, which had a net inflow of 112 million yuan from institutional investors, while Hai Chen Pharmaceutical saw a net outflow of 18.84 million yuan from retail investors [3] - The overall fund flow dynamics suggest a divergence in investment behavior between institutional and retail investors within the sector [2][3]

Core Viewpoint - Haisun Pharmaceutical has successfully renewed the contract for its product, Landeolol Hydrochloride Injection (50mg), and has newly included the 150mg specification in the National Medical Insurance Directory, which is expected to positively impact the company's long-term operations [1]. Group 1: Stock Performance - As of December 8, 2025, Haisun Pharmaceutical's stock closed at 52.31 yuan, up 2.09% from the previous trading day, with a total market capitalization of 6.277 billion yuan [1]. - The stock opened at 51.36 yuan, reached a high of 52.65 yuan, and a low of 51.31 yuan, with a trading volume of 2.26 billion yuan and a turnover rate of 5.28% [1]. Group 2: Product and Revenue Impact - The product Landeolol Hydrochloride Injection (50mg) has a reimbursement price of 168 yuan per unit, while the 150mg specification is set at 389.55 yuan per unit, with the same payment scope [1]. - The agreement for these products is effective from January 1, 2026, to December 31, 2027 [1]. - In 2024, the sales revenue from the 50mg specification is projected to be 337.77 million yuan, accounting for 67.27% of the company's total revenue [1]. - The renewal of the 50mg specification is not expected to affect performance, while the inclusion of the 150mg specification is anticipated to have a positive long-term impact on operations [1].

Group 1 - Cambridge Technology plans to invest 400 million yuan to establish a fund focused on optical devices and chips, aiming to invest in early-stage and growth-stage companies in the hard technology sector [1] - Tunnel Corporation's consortium won a bid for a highway project in Henan with a total investment of 6.49 billion yuan, using a BOT model for a 33.25-year cooperation period [2] - Hongrun Construction won a bid for a project worth 230 million yuan, which represents 3.88% of the company's projected revenue for 2024 [3] Group 2 - Tongrentang's product, Canling Baizhu Powder, received product registration approval from Health Canada, aimed at treating symptoms related to spleen and stomach weakness [4] - Hunan Baiyin announced a scheduled annual maintenance from December 9, 2025, to January 5, 2026, for equipment and facilities [5] - Changchun Gaoxin's subsidiary had two drugs included in the national medical insurance catalog for 2025 [6] Group 3 - Dongfang Securities' chairman resigned due to work relocation [7] - Xuantai Pharmaceutical's product, Sitagliptin Metformin Sustained-Release Tablets, was renewed for inclusion in the national medical insurance catalog [8] - ST Weihai was pre-selected for a smart agriculture EPC project with a bid of 652 million yuan, accounting for 26.27% of the company's projected revenue for 2024 [9] Group 4 - Guoxin Technology successfully tested an anti-quantum password financial POS chip, supporting both traditional and quantum-resistant algorithms [10] - Huaren Health's subsidiary received acceptance for a drug registration application for Lactulose Oral Solution, a common laxative [11] - Ankai Bus reported a 57.71% year-on-year increase in sales for the first 11 months of the year [12] Group 5 - Zhongyan Dadi's subsidiary won a bid for a project worth 73.86 million yuan [13] - Zhejiang Rongtai plans to invest 77 million USD in a factory in Thailand, focusing on mica paper and robot components production [14] - Optoelectronics plans to use up to 450 million yuan of idle funds for cash management [15] Group 6 - Tianyu Biological reported a 45.15% year-on-year decline in sales revenue from pig sales in November [16] - Daqin Railway's cargo transport volume increased by 1.75% year-on-year in November [17] - Yabo Co. won a bid for a heavy truck charging station project worth 3.616 million yuan [18] Group 7 - Hongri Pharmaceutical's product continues to be included in the national medical insurance catalog [19] - Jinggong Steel Structure signed a contract for steel structure installation worth approximately 470 million yuan for an overseas project [20] - Xizang Pharmaceutical's product, Xinhuasuan, continues to be included in the national medical insurance catalog [21] Group 8 - Guangdong Electric Power A announced the successful commissioning of a 1000MW unit at the Maoming Boge Power Plant [22] - Fuan Pharmaceutical's product, Palivizumab Injection, was newly included in the national medical insurance catalog [23] - Lizhu Group reported that 194 products were included in the 2025 national medical insurance catalog [24] Group 9 - Haisan Pharmaceutical's injection of Lantanol was included in the national medical insurance catalog [25] - Zhongtong Bus reported a 39.53% year-on-year increase in sales volume in November [26] - Shaanxi Coal Industry reported a 6.03% year-on-year increase in coal production in November [27] Group 10 - Haooubo's subsidiary received a medical device registration certificate for an IgG4 testing kit [28] - Yaopi Glass plans to invest 690 million yuan in new automotive glass production lines [30] - Huadian International completed the issuance of 2 billion yuan in medium-term notes [31] Group 11 - Zhongzai Zihuan's subsidiary won a bid for a green recycling project worth 205 million yuan [32] - Dabeinong reported a 25.26% year-on-year decline in sales revenue from pig sales in November [33] - Xiangjia Co. reported a 3.77% year-on-year increase in live poultry sales revenue in November [34] Group 12 - Huanxu Electronics reported a consolidated revenue of 5.198 billion yuan in November, a decrease of 3.34% year-on-year [35] - Aonong Biological reported a 72.21% year-on-year increase in pig sales volume in November [36] - Samsung Medical's subsidiary was pre-selected for a procurement project worth approximately 108 million yuan [37]

Core Viewpoint - The company, Hai Chen Pharmaceutical, successfully renewed the contract for its injectable Labetalol Hydrochloride (50mg) and has also included the 150mg version in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1] Group 1 - The injectable Labetalol Hydrochloride (50mg) has successfully renewed its contract [1] - The injectable Labetalol Hydrochloride (150mg) has been included for the first time in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1]

Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have announced the inclusion of Nanjing Haichen Pharmaceutical's injectable Landeolol hydrochloride (50mg) in the National Medical Insurance Directory for 2025, and the first-time inclusion of injectable Landeolol hydrochloride (150mg) [1] Group 1 - Landeolol hydrochloride is a new generation of rapid-acting, ultra-short-acting, highly selective β1 receptor blocker, with a selectivity ratio of approximately 255 times for β1 over β2 receptors, and 8 times more selective than another ultra-short-acting β blocker, Esmolol [2] - The drug has a rapid onset of action (1 to 6 minutes post-administration), a short half-life of about 4 minutes, and minimal negative impact on cardiac hemodynamics and respiratory function [2] - Landeolol is recommended for controlling ventricular rate in acute heart failure patients according to the 2023 National Heart Failure Guidelines, and is also a recommended drug for acute atrial fibrillation in the 2024 Chinese Emergency Management Guidelines [2] Group 2 - The product is projected to achieve sales revenue of 337.77 million yuan in 2024, accounting for 67.27% of the company's total revenue, making it the company's main product [2]